Weinfurt Kevin P, Hall Mark A, Friedman Joëlle Y, Hardy Chantelle, Fortune-Greeley Alice K, Lawlor Janice S, Allsbrook Jennifer S, Lin Li, Schulman Kevin A, Sugarman Jeremy
Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA.
Am Heart J. 2008 Oct;156(4):689-97. doi: 10.1016/j.ahj.2008.06.001.
Little is known about the effects of investigators' financial disclosures on potential research participants.
We conducted a vignette trial in which 470 participants in a telephone survey were randomly assigned to receive a simulated informed consent document that contained 1 of 2 financial disclosures (per capita payments to the research institution or equity ownership by the investigator) or no disclosure. The main outcome measures were trust in medical research and willingness to participate in a hypothetical clinical trial.
Participants in the equity group reported less willingness to participate than participants in the per capita payments group (P = .01) and the no disclosure group (P = .03). Trust in the investigator was highest in the per capita payments group and lowest in the equity group (P < .001). Trust among participants who received no disclosure was also greater than trust among participants in the equity group (P = .04) but did not differ significantly from trust among participants in the per capita payments group (P = .15). Participants in the equity group made 3 times as many negative comments as participants in the per capita payments group; and 10 participants in the equity group spontaneously said they would not participate in the hypothetical trial because of the financial interest, compared with only 1 such participant from the other groups.
Although investigators' financial disclosures in research do not substantially affect willingness to participate, potential research participants are more troubled by equity interests than by per capita payments.
关于研究者的财务披露对潜在研究参与者的影响,人们了解甚少。
我们进行了一项虚拟试验,在电话调查中,470名参与者被随机分配,以接收一份模拟知情同意文件,其中包含两种财务披露情况之一(向研究机构的人均支付或研究者的股权所有权)或不进行披露。主要结局指标是对医学研究的信任度和参与一项假设性临床试验的意愿。
股权组的参与者报告的参与意愿低于人均支付组的参与者(P = 0.01)和未披露组的参与者(P = 0.03)。人均支付组对研究者的信任度最高,股权组最低(P < 0.001)。未披露组参与者之间的信任度也高于股权组参与者之间的信任度(P = 0.04),但与人均支付组参与者之间的信任度无显著差异(P = 0.15)。股权组的参与者给出的负面评价是人均支付组参与者的3倍;股权组有10名参与者自发表示,由于财务利益,他们不会参与该假设性试验,而其他组只有1名这样的参与者。
尽管研究者在研究中的财务披露不会对参与意愿产生实质性影响,但潜在研究参与者对股权利益的困扰大于对人均支付的困扰。